Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 329607, 15 pages
http://dx.doi.org/10.1155/2015/329607
Review Article

Perspective Biological Markers for Autism Spectrum Disorders: Advantages of the Use of Receiver Operating Characteristic Curves in Evaluating Marker Sensitivity and Specificity

1Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Via Belmeloro 8, 40126 Bologna, Italy
2Don Carlo Gnocchi Foundation ONLUS, IRCCS “S. Maria Nascente”, Via Alfonso Capecelatro 66, 20148 Milan, Italy
3ISOF, CNR, 40129 Bologna, Italy
4Comune di Bologna, 40129 Bologna, Italy
5Section of Biochemistry, Biology and Physics, Department of Clinical Sciences, Faculty of Medicine, Polytechnic University of Marche, 60128 Ancona, Italy
6Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences, 40139 Bologna, Italy

Received 14 July 2015; Revised 8 October 2015; Accepted 11 October 2015

Academic Editor: Paul Ashwood

Copyright © 2015 Provvidenza M. Abruzzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Centers for Disease Control and Prevention, “Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010,” MMWR Surveillance Summaries, vol. 63, no. 2, pp. 1–20, 2014, http://www.cdc.gov/media/releases/2014/p0327-autism-spectrum-disorder.html. View at Google Scholar
  2. A. J. Baxter, T. S. Brugha, H. E. Erskine, R. W. Scheurer, T. Vos, and J. G. Scott, “The epidemiology and global burden of autism spectrum disorders,” Psychological Medicine, vol. 45, no. 3, pp. 601–613, 2015. View at Publisher · View at Google Scholar
  3. G. Vivanti, J. Barbaro, K. Hudry, C. Dissanayake, and M. Prior, “Intellectual development in autism spectrum disorders: new insights from longitudinal studies,” Frontiers in Human Neuroscience, vol. 7, article 354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Guthrie, L. B. Swineford, A. M. Wetherby, and C. Lord, “Comparison of DSM-IV and DSM-5 factor structure models for toddlers with autism spectrum disorder,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 52, no. 8, pp. 797.e2–805.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. Kim and C. Lord, “The behavioral manifestations of autism spectrum disorders,” The Neuroscience of Autism Spectrum Disorders, pp. 25–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Brian, S. E. Bryson, and L. Zwaigenbaum, “Autism spectrum disorder in infancy: developmental considerations in treatment targets,” Current Opinion in Neurology, vol. 28, no. 2, pp. 117–123, 2015. View at Publisher · View at Google Scholar
  7. L. D. Wiggins, J. Baio, and C. Rice, “Examination of the time between first evaluation and first autism spectrum diagnosis in a population-based sample,” Journal of Developmental and Behavioral Pediatrics, vol. 27, supplement 2, pp. S79–S87, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. CDC, June 2015, http://www.cdc.gov/ncbddd/autism/screening.html.
  9. C. Betancur, “Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting,” Brain Research, vol. 1380, pp. 42–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. E. Reich and E. S. Lander, “On the allelic spectrum of human disease,” Trends in Genetics, vol. 17, no. 9, pp. 502–510, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Altshuler, M. J. Daly, and E. S. Lander, “Genetic mapping in human disease,” Science, vol. 322, no. 5903, pp. 881–888, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Baker and S. S. Jeste, “Diagnosis and management of autism spectrum disorder in the era of genomics,” Pediatric Clinics of North America, vol. 62, no. 3, pp. 607–618, 2015. View at Publisher · View at Google Scholar
  13. D. H. Geschwind, “Genetics of autism spectrum disorders,” Trends in Cognitive Sciences, vol. 15, no. 9, pp. 409–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Bailey, A. Le Couteur, I. Gottesman et al., “Autism as a strongly genetic disorder: evidence from a British twin study,” Psychological Medicine, vol. 25, no. 1, pp. 63–77, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. D. V. M. Bishop, M. Maybery, A. Maley, D. Wong, W. Hill, and J. Hallmayer, “Using self-report to identify the broad phenotype in parents of children with autistic spectrum disorders: a study using the Autism-Spectrum Quotient,” Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 45, no. 8, pp. 1431–1436, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Bourgeron, “The genetics and neurobiology of ESSENCE: the third Birgit Olsson lecture,” Nordic Journal of Psychiatry, pp. 1–9, 2015. View at Publisher · View at Google Scholar
  17. J. Hallmayer, S. Cleveland, A. Torres et al., “Genetic heritability and shared environmental factors among twin pairs with autism,” Archives of General Psychiatry, vol. 68, no. 11, pp. 1095–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Frye, “Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder,” Epilepsy and Behavior, vol. 47, pp. 147–157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Mead and P. Ashwood, “Evidence supporting an altered immune response in ASD,” Immunology Letters, vol. 163, no. 1, pp. 49–55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Knuesel, L. Chicha, M. Britschgi et al., “Maternal immune activation and abnormal brain development across CNS disorders,” Nature Reviews Neurology, vol. 10, no. 11, pp. 643–660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Ranjan and J. A. Nasser, “Nutritional status of individuals with autism spectrum disorders: do we know enough?” Advances in Nutrition, vol. 6, no. 4, pp. 397–407, 2015. View at Publisher · View at Google Scholar
  22. J. W. Critchfield, S. van Hemert, M. Ash, L. Mulder, and P. Ashwood, “The potential role of probiotics in the management of childhood autism spectrum disorders,” Gastroenterology Research and Practice, vol. 2011, Article ID 161358, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Rossignol, S. J. Genuis, and R. E. Frye, “Environmental toxicants and autism spectrum disorders: a systematic review,” Translational Psychiatry, vol. 4, no. 2, article e360, 2014. View at Publisher · View at Google Scholar
  24. E. Y. Hsiao, S. W. McBride, S. Hsien et al., “Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders,” Cell, vol. 155, no. 7, pp. 1451–1463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Vahter, A. Åkesson, C. Lidén, S. Ceccatelli, and M. Berglund, “Gender differences in the disposition and toxicity of metals,” Environmental Research, vol. 104, no. 1, pp. 85–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Hertz-Picciotto, T. A. Jusko, E. J. Willman et al., “A cohort study of in utero polychlorinated biphenyl (PCB) exposures in relation to secondary sex ratio,” Environmental Health, vol. 7, article 37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. C. Eaves and H. H. Ho, “Young adult outcome of autism spectrum disorders,” Journal of Autism and Developmental Disorders, vol. 38, no. 4, pp. 739–747, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. M. Turner and W. L. Stone, “Variability in outcome for children with an ASD diagnosis at age 2,” Journal of Child Psychology and Psychiatry, vol. 48, no. 8, pp. 793–802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Fein, P. Dixon, J. Paul, and H. Levin, “Brief report: pervasive developmental disorder can evolve into ADHD: case illustrations,” Journal of Autism and Developmental Disorders, vol. 35, no. 4, pp. 525–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Sutera, J. Pandey, E. L. Esser et al., “Predictors of optimal outcome in toddlers diagnosed with autism spectrum disorders,” Journal of Autism and Developmental Disorders, vol. 37, no. 1, pp. 98–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Fein, M. Barton, I.-M. Eigsti et al., “Optimal outcome in individuals with a history of autism,” Journal of Child Psychology and Psychiatry, vol. 54, no. 2, pp. 195–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. H. V. Ratajczak, “Theoretical aspects of autism: biomarkers—a review,” Journal of Immunotoxicology, vol. 8, no. 1, pp. 80–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Voineagu and H. J. Yoo, “Current progress and challenges in the search for autism biomarkers,” Disease Markers, vol. 35, no. 1, pp. 55–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. C. E. Metz, “Basic principles of ROC analysis,” Seminars in Nuclear Medicine, vol. 8, no. 4, pp. 283–298, 1978. View at Publisher · View at Google Scholar · View at Scopus
  35. R. H. Perlis, “Translating biomarkers to clinical practice,” Molecular Psychiatry, vol. 16, no. 11, pp. 1076–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C.-J. Yang, C.-L. Liu, B. Sang, X.-M. Zhu, and Y.-J. Du, “The combined role of serotonin and interleukin-6 as biomarker for autism,” Neuroscience, vol. 284, pp. 290–296, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Alabdali, L. Al-Ayadhi, and A. El-Ansary, “Association of social and cognitive impairment and biomarkers in autism spectrum disorders,” Journal of Neuroinflammation, vol. 11, article 4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Q.-B. Zhang, L.-F. Jiang, L.-Y. kong, and Y.-J. Lu, “Serum Brain-derived neurotrophic factor levels in Chinese children with autism spectrum disorders: a pilot study,” International Journal of Developmental Neuroscience, vol. 37, pp. 65–68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Wang, H. Chen, T. Yu, G. Cui, A. Jiao, and H. Liang, “Increased serum levels of brain-derived neurotrophic factor in autism spectrum disorder,” NeuroReport, vol. 26, no. 11, pp. 638–641, 2015. View at Publisher · View at Google Scholar
  40. Y. A. Al-Yafee, L. Y. Al- Ayadhi, S. H. Haq, and A. K. El-Ansary, “Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia,” BMC Neurology, vol. 11, article 139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. Q.-B. Zhang, S.-J. Gao, and H.-X. Zhao, “Thioredoxin: a novel, independent diagnosis marker in children with autism,” International Journal of Developmental Neuroscience, vol. 40, pp. 92–96, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. A. K. El-Ansary, A. G. Ben Bacha, and L. Y. Al- Ayahdi, “Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia,” Lipids in Health and Disease, vol. 10, article 63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. K. El-Ansary, A. G. Bacha, and L. Y. Al- Ayahdi, “Plasma fatty acids as diagnostic markers in autistic patients from Saudi Arabia,” Lipids in Health and Disease, vol. 10, article 62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. El-Ansary and L. Al-Ayadhi, “Neuroinflammation in autism spectrum disorders,” Journal of Neuroinflammation, vol. 9, article 265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. A. El-Ansary and L. Al-Ayadhi, “Lipid mediators in plasma of autism spectrum disorders,” Lipids in Health and Disease, vol. 11, article 160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. A. K. El-Ansary, A. G. Ben Bacha, and L. Y. Al-Ayadhi, “Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia,” Journal of Neuroinflammation, vol. 8, article 142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. H.-X. Zhao, S.-S. Yin, and J.-G. Fan, “High plasma neopterin levels in Chinese children with autism spectrum disorders,” International Journal of Developmental Neuroscience, vol. 41, pp. 92–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. C. L. Yan, J. Zhang, and Y. Hou, “Decreased plasma levels of lipoxin A4 in children with autism spectrum disorders,” NeuroReport, vol. 26, no. 6, pp. 341–345, 2015. View at Publisher · View at Google Scholar
  49. N. J. Heyer, D. Echeverria, and J. S. Woods, “Disordered porphyrin metabolism: a potential biological marker for autism risk assessment,” Autism Research, vol. 5, no. 2, pp. 84–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Cozzolino, L. De Magistris, P. Saggese et al., “Use of solid-phase microextraction coupled to gas chromatography–mass spectrometry for determination of urinary volatile organic compounds in autistic children compared with healthy controls,” Analytical and Bioanalytical Chemistry, vol. 406, no. 19, pp. 4649–4662, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Nadal-Desbarats, N. Aïdoud, P. Emond et al., “Combined 1H-NMR and 1H–13C HSQC-NMR to improve urinary screening in autism spectrum disorders,” The Analyst, vol. 139, no. 13, pp. 3460–3468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Testa, F. Nuti, J. Hayek et al., “Di-(2-ethylhexyl) phthalate and autism spectrum disorders,” ASN Neuro, vol. 4, no. 4, pp. 223–229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S.-O. Li, J.-L. Wang, G. Bjørklund, W.-N. Zhao, and C.-H. Yin, “Serum copper and zinc levels in individuals with autism spectrum disorders,” NeuroReport, vol. 15, pp. 1216–1220, 25. View at Publisher · View at Google Scholar · View at Scopus
  54. A. K. El-Ansary, A. B. Bacha, and L. Y. Ayahdi, “Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia,” Clinical Biochemistry, vol. 44, no. 13, pp. 1116–1120, 2011. View at Publisher · View at Google Scholar
  55. L. Y. Al-Ayadhi, A. G. Ben Bacha, M. Kotb, and A. K. El-Ansary, “A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics,” Behavioral and Brain Functions, vol. 8, article 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Ghezzo, P. Visconti, P. M. Abruzzo et al., “Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features,” PLoS ONE, vol. 8, no. 6, Article ID e66418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Kreyszig, Advanced Engineering Mathematics, Wiley, 4th edition, 1979. View at MathSciNet